With the addition of targeted therapies directed against activating BRAF mutations (found in ∼40% of cutaneous melanomas), over half of patients today with advanced cutaneous melanoma will survive for more than 5 years after their initial diagnosis. This evidence concerns the gene BRAF and cutaneous melanoma.